Covalon to Present SurgiClear(TM) at AORN Surgical Conference and Expo
Share:
MISSISSAUGA, ON, – Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced that it will be featuring SurgiClear™ at the Association of periOperative Registered Nurse's (AORN) Surgical Conference and Expo, the largest international gathering of perioperative registered nurses worldwide.
SurgiClear™ is one of the most advanced post-operative dressings on the market because of its patent pending dual antimicrobial clear silicone adhesive. SurgiClear's combination of chlorhexidine and silver is proven to have a synergistic effect against some of the most common surgical site infection bacteria(i) and SurgiClear's soft silicone adhesive will not cause adhesive related skin injury or pain during dressing changes(ii).
Covalon will also be showcasing its dual antimicrobial clear silicone adhesive securement dressing IV Clear™, as well as its MediClear™ line of post-op incision and scar management dressings.
"We are delighted about the opportunity to engage with perioperative clinicians regarding the benefits that SurgiClear can bring to both their patients and practice." said John R. Hands, Covalon's Executive Vice President. "Clinicians who have used SurgiClear for more than 15 months have communicated to us experiences such as reduced surgical site infections and lower antibiotic use which is very exciting. We look forward to presenting all the benefits of our surgical dressings at AORN." he continued.
In addition to exhibiting, Covalon will be presenting two scientific posters at AORN entitled Novel PreOperative Skin Preparation: Eliminating the "Patient Compliance" Problem and Post-operative Wound Care: The Effect of Variability in Exudate Flow Rate on Dressing Uptake in an in Vitro Wound Model.
Visit Covalon at booth 228 at the AORN Surgical Conference and Expo on April 3-5 at the Anaheim Convention Centre.
About Covalon
Covalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that help save lives around the world. Covalon's patented technologies, products and services address the advanced healthcare needs of medical device companies, healthcare providers and individual consumers. Covalon's technologies are used to prevent, detect and manage medical conditions in specialty areas such as wound care, tissue repair, infection control, disease management, medical device coatings and biocompatibility. To learn more about Covalon, visit our website at www.covalon.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
(i) A Laboratory Study of the Synergistic Effect of Chlorhexidine and Silver, Blom, Kristina Werthen, Maria et al. American Journal of Infection Control , Volume 43 , Issue 6 , S22
(ii) A Human Repeat Patch Test Study, DiTizio et al.
http://www.wounds-uk.com/case-series/harrogate-2014-conferenceposters  Â
SOURCE Covalon Technologies Ltd.
CONTACT:
To learn more about Covalon, please contact:
Brian Pedlar
CEO, Covalon Technologies Ltd.
Email: bpedlar@covalon.com
Phone: 905.568.8400 x 233
Toll free: 1.877.711.6055
Web Site: www.covalon.com Â
